Search company, investor...

Founded Year



Loan | Alive

Total Raised


Last Raised

$3.5M | 4 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+30 points in the past 30 days

About Aptima

Aptima is a company focused on improving and optimizing performance in technology-intensive, mission-critical settings. The company offers solutions that measure, assess, inform, and augment human performance, with a particular emphasis on human-AI teaming, unobtrusive measurement, data analytics, and intelligent interfaces. Aptima primarily serves sectors such as defense, intelligence, aviation, law enforcement, and healthcare. It was founded in 1995 and is based in Woburn, Massachusetts.

Headquarters Location

12 Gill Street Suite 1400

Woburn, Massachusetts, 01801,

United States




Aptima Patents

Aptima has filed 52 patents.

The 3 most popular patent topics include:

  • artificial intelligence
  • educational technology
  • machine learning
patents chart

Application Date

Grant Date


Related Topics




Artificial neural networks, Machine learning, Classification algorithms, Artificial intelligence, Relational database management systems


Application Date


Grant Date



Related Topics

Artificial neural networks, Machine learning, Classification algorithms, Artificial intelligence, Relational database management systems



Latest Aptima News

Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System

Feb 2, 2024

Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System February 2, 2024 Through a Combination of Advanced Imaging and Novel Artificial Intelligence, Latest Diagnostic System for Cervical Cancer Screening Can Help More Accurately Detect Disease, Improve Workflow and Enhance Patient Care MARLBOROUGH, Mass.–(BUSINESS WIRE)– $HOLX #cervicalcancerscreening –Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has received clearance from the U.S. Food and Drug Administration (FDA), making it the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. “Hologic is a leading innovator in women’s health with a commitment to advancing cervical and breast cancer screening technologies, from the first liquid-based cytology test to the first 3D mammography system and now the first FDA-cleared digital cytology platform,” said Jennifer Schneiders, Ph.D., President, Diagnostic Solutions at Hologic. “Our technologies have had a tremendous impact on decreasing cancer rates in women, and we are incredibly excited by the promise of Genius Digital Diagnostics. The system delivers more actionable and accurate insights for laboratories and healthcare professionals to enhance patient care.” In its most recent update , the American Cancer Society estimated that 13,820 cases of invasive cervical cancer will be diagnosed in the United States in 2024, and approximately 4,360 women will die from the disease. Detecting and identifying cervical cancer in the earliest stages is critical to effective prevention and treatment. Screenings for cervical cancer include a Pap test, where a sample is generally collected at an OB-GYN office, and the cervical cells are sent to a lab where they are transferred to a glass slide. To date, this glass slide has been reviewed under a microscope. With the Genius Digital Diagnostics System, the glass slides are digitally imaged and an artificial intelligence algorithm is applied to pinpoint the cells that cytologists and pathologists should review. The new process and technology demonstrated an overall improvement in sensitivity without a corresponding decrease in specificity. Notably, there was a 28% reduction in false negatives of high-grade squamous intraepithelial and more severe lesions compared to microscopic review.1 The Genius Digital Diagnostics System will help laboratories arm healthcare professionals with the information they need to guide more timely and effective treatment decisions for patients. The Genius Digital Diagnostics System also offers the opportunity for greater collaboration across lab and other healthcare settings. The system allows cytologists and pathologists to securely review cases remotely, so patients can benefit from the collective knowledge of geographically dispersed experts. The Genius Digital Diagnostics System consists of the Genius™ Digital Imager for image acquisition, the Genius™ Cervical AI algorithm for image analysis, the Genius™ Image Management Server for image storage and the Genius™ Review Station for local or remote case review. The complete system is scalable and designed to fit the present and future needs of laboratories. The Genius Digital Diagnostics System is already commercially available in Europe, Australia and New Zealand. Commercial availability in the U.S. is expected in early 2024. About Cervical Cancer Screening Cervical cancer is preventable and, if caught early, can be highly treatable. Co-testing — combining a Pap test with an HPV test — has been shown to be the most sensitive testing option for cervical cancer screening compared to either test used alone.2,3,4,5 Hologic pioneered the first FDA-approved liquid-based cytology test, the ThinPrep® Pap test, and the first FDA-approved mRNA-based HPV test, the Aptima® HPV Assay. Healthcare professionals have the choice to perform a co-test with ThinPrep and Aptima. About Hologic, Inc. Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding; and advanced vessel sealing and dissection devices. The company also champions women through the Hologic Global Women’s Health Index , which provides a science-backed data framework for improving women’s well-being. Forward-Looking Statements This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based. Hologic, The Science of Sure, Aptima, Genius and ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Source: Hologic, Inc. 1 Genius Digital Diagnostics System with the Genius Cervical AI Algorithm Instructions for Use AW-23890-001. Hologic, Inc.; 2024 2 Austin RM, et al. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV co-testing. Am J Clin Pathol.2018;150(5):385-392. doi: 10.1093/ajcp/aqy114 (Study included the ThinPrep® Pap test, ThinPrep imaging, digene HPV, Cervista HPV and Aptima HPV). 3 Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/ cncy.21544 (Study included ThinPrep, SurePath and Hybrid Capture 2 assay). 4 Kaufman H, et al. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074 (Study included ThinPrep Pap test, ThinPrep imaging, SurePath Pap test, SurePath imaging, Aptima HPV assay and Hybrid Capture 2 HPV assay). 5 Zhou H, et al. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. Cancer Cytopathol. 2016 May;124(5):317-23. doi: 10.1002/cncy.21687. (Study included Cobas HPV, SurePath and ThinPrep).

Aptima Frequently Asked Questions (FAQ)

  • When was Aptima founded?

    Aptima was founded in 1995.

  • Where is Aptima's headquarters?

    Aptima's headquarters is located at 12 Gill Street, Woburn.

  • What is Aptima's latest funding round?

    Aptima's latest funding round is Loan.

  • How much did Aptima raise?

    Aptima raised a total of $3.5M.

  • Who are the investors of Aptima?

    Investors of Aptima include Paycheck Protection Program and U.S. Department of Defense.

  • Who are Aptima's competitors?

    Competitors of Aptima include ALKU and 4 more.


Compare Aptima to Competitors

Kantar Logo

Kantar is a data investment management company. The company offers research, insight, information, and consultancy services. It enables companies to offer clients business insights at every point of the consumer cycle. Kantar was founded in 1993 and is based in London, U.K.


NOCD provides telehealth services for the treatment of obsessive-compulsive disorder (OCD). The company offers online therapy sessions through its platform, connecting patients with licensed therapists who specialize in exposure and response prevention therapy (ERP), a recognized treatment for OCD. In addition to live video sessions, the platform provides access to therapeutic tools, exercises, and peer communities for continuous support. It was founded in 2014 and is based in Chicago, Illinois.

Global Government Solutions

Global Government Solutions, also known as G²S Corporation, specializes in providing consultation services across multiple sectors including public health, information technology, and financial and program management. The company offers healthcare marketing engagement and training, management support, advisory and assistance services, as well as IT services leveraging advanced business platforms and emergent trends. G²S Corporation also provides financial management expertise, applying Federal Acquisition Regulation and Cost Accounting Standards to administer contracts for government agencies. It was founded in 2009 and is based in San Antonio, Texas.

Oxford Global Resources Logo
Oxford Global Resources

Oxford Global Resources is a professional services company operating in various sectors including life sciences, consumer and industrial, technology and communications, healthcare, financial services, and the public sector. The company offers tailored solutions such as staffing, consulting, and project management, with a focus on areas like workforce mobilization, digital transformation, and modern enterprise. It primarily serves industries such as life sciences, technology and communications, and the public sector. It was founded in 1984 and is based in Beverly, Massachusetts.

SeKON Logo

SeKON is a mid-tier business specializing in federal health IT systems and professional services advisory, focusing on cultural, operational, and technical transformation. The company offers a range of services including cybersecurity, data analytics, digital transformation, and health and clinical information integration. SeKON primarily serves federal government agencies such as NIH, SAMHSA, CDC, CMS, and DHA. It is based in Reston, Virginia.

NielsenIQ Logo

NielsenIQ is a leading consumer intelligence company operating in the data analytics and market research industry. The company provides comprehensive insights into consumer buying behavior, helping businesses understand their customers, innovate their products, refine their assortments, and optimize their performance. NielsenIQ primarily serves sectors such as beauty, beverage alcohol, financial services, government, media and advertising technology, packaging, and pet industries. It was founded in 1923 and is based in Chicago, Illinois.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.